Home  »  Science   »  Analyzing Structure Therapeutics Inc.(NASDAQ: GPCR...

Analyzing Structure Therapeutics Inc.(NASDAQ: GPCR) Stock as a Disaster or Opportunity

In the last trading session, 1.74 million Structure Therapeutics Inc. (NASDAQ:GPCR) shares changed hands as the company’s beta touched 0. With the company’s per share price at $35.85 changed hands at $3.2 or 9.80% during last session, the market valuation stood at $1.32B. GPCR’s last price was a discount, traded about -18.69% off its 52-week high of $42.55. The share price had its 52-week low at $20.80, which suggests the last value was 41.98% up since then. When we look at Structure Therapeutics Inc.’s average trading volume, we note the 10-day average is 0.6 million shares, with the 3-month average coming to 430.26K.

Analysts gave the Structure Therapeutics Inc. (GPCR) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended GPCR as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Structure Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.22.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Structure Therapeutics Inc. (NASDAQ:GPCR) trade information

Instantly GPCR was in green as seen at the end of in last trading. With action 21.61%, the performance over the past five days has been green. The jump to weekly highs of 36.25 on Monday, 09/18/23 added 9.80% to the stock’s daily price. The company’s shares are showing year-to-date upside of 37.88%, with the 5-day performance at 21.61% in the green. However, in the 30-day time frame, Structure Therapeutics Inc. (NASDAQ:GPCR) is 30.22% up. Looking at the short shares, we see there were 2.41 million shares sold at short interest cover period of 3.73 days.

The consensus price target for the stock as assigned by Wall Street analysts is $48.50, meaning bulls need an upside of 26.08% from its current market value. According to analyst projections, GPCR’s forecast low is $40.00 with $58.00 as the target high. To hit the forecast high, the stock’s price needs a -61.79% plunge from its current level, while the stock would need to soar -11.58% for it to hit the projected low.

Structure Therapeutics Inc. (GPCR) estimates and forecasts

Data shows that the Structure Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 55.06% over the past 6 months, a 84.03% in annual growth rate that is considerably higher than the industry average of 11.90%.

The 2023 estimates are for Structure Therapeutics Inc. earnings to decrease by -20.70%.

GPCR Dividends

Structure Therapeutics Inc. is expected to release its next quarterly earnings report in October.

Structure Therapeutics Inc. (NASDAQ:GPCR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.10% of Structure Therapeutics Inc. shares while 41.29% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 41.33%. There are 41.29% institutions holding the Structure Therapeutics Inc. stock share, with Deep Track Capital, Lp the top institutional holder. As of Jun 29, 2023, the company held 6.92% of the shares, roughly 2.65 million GPCR shares worth $110.03 million.

Price (T.Rowe) Associates Inc holds the second largest percentage of outstanding shares, with 4.63% or 1.77 million shares worth $73.72 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Price (T.Rowe) New Horizons Fund and Federated Hermes Kaufmann Fund. With 0.71 million shares estimated at $29.5 million under it, the former controlled 1.85% of total outstanding shares. On the other hand, Federated Hermes Kaufmann Fund held about 1.31% of the shares, roughly 0.5 million shares worth around $12.71 million.

On Key

Related Posts